Then, on 6 March, a host of prominent industry experts, including representatives from the European Medicines Agency (EMA) and the Directorate General for Health and Consumer Affairs (DG SANCO), will be invited to a meet and greet breakfast and a TIRS Editorial lunch.

Dr. Spielberg said: “I am greatly looking forward to welcoming participants to the EuroMeeting 2013 in Amsterdam. This year promises to be an insightful event with 110 comprehensive sessions.”

More than 300 high-profile speakers, moderators, and panelists from around the world are set to attend EuroMeeting 2013, substantiating the meeting’s claim to being the most important event in the medicines development calendar.

The meeting will feature 200 exhibitors and bring together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centres, health ministries, and delegates from patient organizations to share knowledge focusing on better public health protection, greater transparency of processes, and the rational use of medicinal products.

Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time.